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Deep sequencing of the full-length hepatitis B virus (HBV) genome 
provides the opportunity to determine the extent to which viral 
diversity, genotype, polymorphisms, insertions and deletions may 
influence presentation and outcomes of disease. Increasing 
experience with analysis of HBV genomic data opens up the potential 
for using these data to inform insights into pathophysiology of 
infection and to underpin decision making in clinical practice. We here 
set out to undertake whole genome HBV sequencing from an adult 
who presented acutely unwell with a new diagnosis of HBV infection, 
and tested positive for both HBV anti-core IgM and IgG, possibly 
representing either acute hepatitis B infection (AHB) or chronic 
hepatitis B with an acute reactivation (CHB-AR). The distinction 
between these two scenarios may be important in predicting 
prognosis and underpinning treatment decisions, but can be 
challenging based on routine laboratory tests. Through application of 
deep whole-genome sequencing we typed the isolate as genotype-D1, 
and identified several minority variants including G1764A and G1986A 
substitutions in the pre-core promoter and pre-core regions, which 
support CHB-AR rather than AHB. In the longer term, enhanced deep 
sequencing data for HBV may provide improved evidence to 
distinguish between acute and chronic infection, to predict outcomes 
and to stratify treatment.
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Abbreviations
•     AHB – Acute hepatitis B
•     CHB – Chronic hepatitis B
•     CHB-AR – Acute reactivation of chronic hepatitis B
•     Anti-HBc-IgM – Hepatitis B anti-core IgM antibody
•     HBsAg – Hepatitis B surface antigen
•     TDF - Tenofovir disoproxil fumarate
•     S/CO – Sample to cut-off ratio
•     PEI units – Paul Ehrlich Institut units
•     HBeAg – Hepatitis B e antigen
•     NGS – Next generation sequencing
Introduction
The course of hepatitis B virus (HBV) infection depends on 
the interplay between the virus and host immune system, with 
variable outcomes that include clearance, control, chronicity, 
cirrhosis and cancer. One other important disease manifestation 
is that of acute reactivation of chronic hepatitis B infection 
(CHB-AR), in which a previously quiescent virus causes a flare 
of hepatitis, typically characterised by a sudden rise in both 
serum alanine aminotransferase (ALT) and HBV DNA viral 
load1. There are two different scenarios that may be referred 
to as CHB-AR: (i) patients with a consistently positive HBV 
surface antigen (HBsAg) test, but a baseline low or undetect-
able viraemia, followed by a sudden rise in HBV viral load (VL); 
(ii) patients in whom HBsAg has been cleared completely, but 
subsequently becomes detectable again in serum, usually in the 
context of immunosuppression2,3, associated with concurrent 
bacterial or HIV infection, in times of emotional or physical 
stress, and associated with pregnancy4–6.
Traditionally the presence of HBV anti-core IgM (anti-HBc-IgM) 
is considered a marker of acute hepatitis B (AHB) infection. 
However, with improvements in sensitivity of the IgM ELISA 
assay, low titres of IgM can now be detected in up to 70% 
of cases of CHB-AR, making it difficult to distinguish between 
the two syndromes7–9. Production of anti-HBc-IgM during 
CHB-AR may be due to alteration of antigenic epitopes 
leading to new antibody production, or increased display of 
core antigen due to hepatocellular lysis during CHB-AR10,11. 
One study estimated 27% of presumed AHB cases were in fact 
CHB-AR12, and in endemic settings this may be even higher, with 
up to 70% of acute presentations being associated with chronic 
infection7. The annual rate of CHB-AR has been estimated 
at 3.3%13.
The distinction between AHB and CHB-AR can be prognosti-
cally important and can influence treatment approaches with 
antiviral agents. CHB-AR typically runs a less predictable 
course: in most cases, liver function tests (LFTs) and HBV DNA 
levels return to baseline but future flares of hepatitis can occur. 
CHB-AR may also be associated with severe hepatitis, occasion-
ally leading to acute-on-chronic liver failure and death14. After 
the acute flare has passed, the longer-term risks of cirrhosis and 
hepatocellular carcinoma associated with CHB are still present. 
In severe cases of CHB-AR, tenofovir disoproxil fumarate (TDF) 
is recommended, with some evidence that it reduces mortality15. 
In contrast, AHB flares may resolve spontaneously and can result 
in HBsAg clearance without any specific treatment.
To distinguish AHB from CHB-AR, several studies have 
investigated quantitative anti-HBc-IgM7,16,17. However, at present 
there is a lack of standardisation of commercial assays and no 
consensus as to a valid clinical threshold10,18. HBV DNA levels 
are typically higher in CHB-AR, but may be low or undetect-
able by the time new acute infection presents with clinical 
symptoms7,10,16, due to the rapid immunological clearance of 
HBV DNA in AHB19. Some studies suggest that higher ALT, 
aspartate aminotransferase (AST) and bilirubin (BR) levels 
point to AHB16,20, but this is not consistent7. The combination of 
anti-HBc-IgM levels and quantitation of HBV DNA and/or 
HBsAg may become more sensitive and specific in distinguish-
ing between AHB vs CHB-AR16,21, but this approach is not yet 
standardised.
As next generation sequencing (NGS) platforms become more 
accessible and affordable, there is potential to analyse HBV 
sequences to greater depth and accuracy to aid distinction of 
clinical syndromes and to inform treatment decisions22. Multiple 
studies have focussed on HBV sequence polymorphisms 
associated with AHB versus CHB-AR, but most have focused on 
short regions of the genome using Sanger sequencing23–26, and 
there is limited insight into specific polymorphisms or features 
that might be helpful in discriminating between these two 
syndromes.
We here report the case of a patient with no known history of 
viral hepatitis presenting to hospital with an acute episode of 
hepatitis, and testing positive for HBsAg. Based on routine 
serological markers undertaken in the clinic, it was not possible 
to distinguish between AHB versus CHB-AR. We applied full 
length sequencing of HBV using Illumina deep sequencing to 
help identify any sequence polymorphisms that could help to 
distinguish between acute vs. chronic infection. The case 
illustrates the diagnostic difficulties that can be associated with 
the presentation of an acute flare of HBV and highlights the 
future potential for deep sequencing approaches to contribute to 
diagnosis, prognosis, and treatment decisions.
Case report
A middle-aged man of Pakistani origin presented to a UK 
hospital with jaundice, dark urine, headache, fatigue and flu-like 
symptoms (Oxford viral hepatitis cohort, study ID: 1745). He 
had been unwell in the week preceding admission but had not 
sought prior medical attention. He was born in Pakistan but 
     Amendments from Version 1
There was an error in the abstract and Table 1 regarding the 
position of a key mutation in the HBV genome. Position 1896 was 
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the end of the article
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has been resident in the UK since childhood. He reported a 
history of HBV infection in an aunt in Pakistan; his wife 
and children in the UK all tested HBsAg-negative. He has no 
occupational risk factors for infection, does not drink alcohol, 
takes no medications, and is usually fit and active. He had 
recently returned from visiting Malaysia, but denied any risk 
factors for recent acquisition of HBV infection. On examination 
he was haemodynamically stable. He had conjunctival icterus, but 
there was no hepatosplenomegaly and his abdomen was soft and 
non-tender.
On further discussion, he reported several similar episodes 
of illness over preceding years, albeit less severe and without 
objective jaundice; on these grounds he had never previously 
presented for clinical review. Together with the absence of any 
risk factors for acute infection, this history raised the possibility 
of recurrent flares of hepatitis, leading us to consider whether 
this was a presentation of CHB-AR rather than AHB. We could 
not identify any precipitating factors leading to reactivation; 
specifically, there were no risk factors for immunocompromise.
At presentation, ALT was 608 IU/L (reference range 10–45 
IU/L), BR 138 μmol/L (reference range 0–21 μmol/L), platelets 
121 × 109/L (reference range 150–400 × 109/L) and prothrombin 
time 17.7 seconds (reference range 9–12 seconds). He tested 
positive for HBsAg, anti-HBc-IgM and IgG. Anti-HBc-IgM 
levels were 7.43 S/CO (reactive >1 S/CO corresponding to 
50 PEI units). Hepatitis B e-antigen (HBeAg) was negative, 
hepatitis B e-antibody (anti-HBe) positive. HBV DNA was 
5.5 log
10
 IU/mL. Hepatitis A, C, D, E and HIV were negative. 
Elastography score was elevated at 38.7kPa (normal range 
2–7kPa). A liver ultrasound was normal with no intrahepatic 
or biliary duct dilatation and no evidence of liver fibrosis. 
At the time of presentation, the overall picture was deemed 
most consistent with acute HBV infection, with the elevated 
elastography score reflecting acute liver inflammation.
He received supportive care including intravenous fluids and 
close monitoring, and made a gradual clinical recovery over 
2–3 months. Nucleos(t)ide analogue therapy was deferred on the 
grounds of gradual improvement and a chance of spontaneous 
clearance of HBsAg. At three months post-presentation, blood 
markers had all improved (HBV DNA 2.9 log
10
 IU/mL, ALT 
41 IU/L, BR 40μmol/L (Figure 1)). Anti-HBc-IgM was still 
reactive but had decreased to 3.37 S/CO. At six months post-
presentation, HBsAg remained positive and he therefore now 
meets the case definition for chronic infection. He chose to 
remain off therapy, but is under close follow-up to allow us 
to continue to review the indications for antiviral treatment 
based on clinical progress and guidelines27.
Application of Illumina Sequencing of HBV
Through application of Illumina sequencing to a baseline plasma 
sample (collected at the time of first presentation to hospital), 
we generated 1.28 million total reads, of which 74% mapped 
to HBV. The consensus sequence was 3182 nucleotides long 
and mapped to genotype D, clustering within subtype D1, mak-
ing it most closely related to other published sequences from 
Pakistan (Figure 2). After de-duplication, the median coverage 
was 18,069 reads per site (Figure 3A). In this deep sequence 
dataset, 2.5% (80/3182) of nucleotide positions had a Shannon 
entropy score of >0.1 (Figure 3B). These sites were evenly 
distributed across the genome with no obvious concentration 
in any particular gene.
In this deep sequence dataset, 2.5% (80/3182) of nucleotide 
positions had a Shannon entropy score of >0.1 (Figure 2B). 
These sites were evenly distributed across the genome with no 
Figure 1. Laboratory timeline for an adult presenting with acutely deranged liver function tests in the setting of HBV infection. 
Anti-HBc IgM and IgG were both present throughout the timeline. Blood for whole genome sequencing was taken at presentation (week 0). 
Elastography score improved to 25.3kPa 6 months later then down to 20.7kPa at one year after initial presentation.
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Figure 2. Maximum likelihood phylogenetic tree of HBV sequence derived from an adult male presenting acutely with 
HBV infection. Consensus HBV sequence for patient 1745 is shown (blue) alongside representative genotype and subtype reference 
sequences, and all full-length HBV sequences from Pakistan (green) and Malaysia (red) from GenBank. Reference sequences28: A (X02763), 
B (GQ205440), C (KP017269), D1 (clade 1): KP322600, D1 (clade 2): JN040807, D2: KR905424, D3: KP322602, D5: KP322603, D4/7: FJ692533 
(D4 and D7 cluster closely and this sequence is representative of the clade including both genotypes). Bootstrap replicates of 1000 
generated using MEGA7. Bootstrap values of >70 are shown. Scale bar shows substitutions per site. The sequences in GenBank from Pakistan 
mapped to either subtype D1 (6/7 sequences) or D3 (1/7 sequences) whilst Malaysian sequences map to subtype D2 (3/3 sequences).
obvious concentration in any particular gene. Nucleotide 
diversity has been reported to be lower in acute HBV infec-
tion, possibly due to a small number of variants initiating 
new infection29,30. However, other reports have shown low viral 
diversity in CHB, mostly in the context of HBeAg positivity and 
high viral loads where immune pressure may be minimal31,32. 
The top six most diverse sites in this HBV genome were 
all located in non-overlapping regions in the polymerase 
gene, where mutations are least likely to have an impact on 
viral fitness and  high diversity, as previously described22,33,34.
The most prevalent minority variant mutations in our HBV 
sequences were G1896A, G1899A and G1764A (precore/core 
and basal core promotor sequences respectively) (Table 1). 
G1896A converts codon 28 from tryptophan (TGG) to a stop 
codon (TAG) and terminates the translation of the HBeAg 
precursor35. Mutations at amino acid level were also seen in 
surface antigen (V190A and T127P), both of which have been 
associated with CHB-AR in the context of immunosuppression 
(Table 1). Several immune escape mutations have been iden-
tified in the literature in patients presenting with AHB, none 
of which were present in our sequences36 (Table 1). Minority 
variant deletions occurring in ≥10% of viral sequencing 
reads were detected at nt 1419–1426 and nt 1860–1865 in the 
RT/X-gene and pre-core genes respectively (Figure 3C). Muta-
tions at nt 1862 have previously been shown to impair genome 
replication37, but deletions in either region have not been 
reported in the literature to date, to the best of our knowledge.
There are clinical and laboratory features of this case suggestive 
of both AHB and CHB-AR, summarised in Table 2. Overall, we 
conclude that this patient is most likely to have presented with 
CHB-AR, on a background of infection early in life in Pakistan. 
Discussion
This case demonstrates how difficult it can be to distinguish 
between AHB and CHB-AR, and highlights inconsistencies in 
the way the term ‘reactivation’ is used. We have illustrated the 
potential application of whole genome deep sequencing data 
to identify sequence changes in the HBV genome that may be 
associated with a specific disease presentation.
Quantitative anti-HBc-IgM, HBsAg and HBV DNA are currently 
the best tools with which to distinguish between AHB and 
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Figure 3. HBV genome map showing sequencing coverage, diversity and deletions for a genotype D sequence derived from a 
patient with acute biochemical hepatitis. In each case, the nucleotide position is shown on the x-axis, with the approximate positions of 
corresponding genes indicated in the bar at the top (adapted from McNaughton et al.22). A: Illumina data showing read coverage (log scale) 
at each nucleotide site along the HBV genome. The drop in coverage around nt 1000-1600 corresponds to the single stranded portion 
of the genome. B: Shannon entropy calculated for each site along the genome. Shaded areas represent non-overlapping sections of the 
genome and the horizontal dotted line isolates the top six most diverse sites. C: Locations of minority variant deletions, with a threshold 
indicated at ≥10% to identify the deletions most likely to be relevant. Deletions shown at the start of the genome are likely to represent an 
artefact of the mapping (short reads derived from a circular genome have been mapped onto a linear construct). 
CHB-AR. However, further efforts are required to define 
diagnostic thresholds, and clinicians should consider other 
factors that might help to discriminate between AHB and 
CHB-AR. In the longer term, generation and publication of more 
HBV sequencing data are essential in order to improve insights 
into sequence motifs that are associated with specific clinical 
syndromes and outcomes of HBV infection. In order to meet 
the ambitious United Nations Sustainable Development Goals 
target for elimination of viral hepatitis as a public health threat 
by the year 203038, action is required to improve the provi-
sion of treatment to those at highest risk of long-term com-
plications and to reduce transmission at a population level. 
High resolution sequencing data is one way to advance our 
understanding of the outcomes and biology of infection, and 
to improve treatment stratification.
At present, it is difficult to come to any definite conclusion 
by analysing HBV sequence data from one patient at a single 
timepoint. Longitudinal sequencing would be helpful to detect 
any changes in HBV sequence, but the current sensitivity of 
NGS platforms limits our ability to generate sequences as 
HBV VL falls <104 IU/ml30,39. Our patient had been unwell 
prior to hospital presentation, but we do not have clinical or 
biochemical data for this period, which could have shed 
further light on his illness (for example, changes in anti-HBc-IgM 
titre).
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Table 2. Summary of factors in the case of an adult presenting with an acute biochemical hepatitis favouring either AHB or 
CHB-AR.
Evidence in support of AHB Evidence in support of CHB-AR
Patient history      •     Recent travel to Malaysia as a possible 
risk factor for HBV acquisition (prevalence 
estimated to be up to 9%47).
     •     No household members are HBsAg 
positive, and no (known) history of HBV 
infection in parents or siblings.
     •     No precipitating factors identified for 
CHB-AR
     •     Patient’s own description of previous similar events, possibly 
representing previous episodes of CHB-AR.
     •     Origin in Pakistan where HBV prevalence is estimated to be 




     •     Relatively high peak bilirubin level20  
(227 mol/L at highest). 
     •     Some studies indicate an anti-HBc-IgM S/CO >10 is indicative 
of AHB17. In this case, the S/CO level of 7.43 does not meet 
this threshold, suggesting CHB-AR may be more likely.
     •     High HBV DNA level at diagnosis (5.5 log10 IU/ml). Studies 
have indicated this level of HBV DNA fits more with  
CHB-AR7,16,50.
     •    Relatively low rise in ALT (486 IU/ml at peak).
     •     Patient remains HBsAg-positive six months after initial 
presentation. Since >90% of adults clear AHB infection, 




     •     No polymorphisms associated with  
CHB-AR identified at consensus level
     •     Viral sub-genotype is D1, known to circulate in Pakistan51, 
suggesting infection early in life, and supported by 6/7 of 
the other sequences from Pakistan being D1.
     •     Presence of several minority variant mutations associated 
with CHB-AR and lack of mutations described to be 
associated with AHB.
     •     Relative lack of nucleotide diversity in the HBV genome could be a feature of AHB due to a small number of 
HBV variants establishing new infection. Could also represent high viral load CHB where there is reduced 
immune selection and unregulated replication of conserved viral populations.
     •    The pattern of deletions seen here has not been reported as typical of association with either AHB or CHB-AR.
AHB – acute hepatitis b virus infection; CHB-AR – acute reactivation of chronic hepatitis b virus infection; S/CO – sample to cut off ratio.
The sequence data available for comparison are extremely 
limited and there is a lack of representation from diverse 
geographical regions and different genotypes. Strikingly, 
in GenBank there are currently only seven full length HBV 
genome sequences from Pakistan (all genotype D), limiting the 
contribution made by phylogenetic analysis to help discern the 
origin of our patient’s HBV infection.
Conclusion
Current laboratory methods deployed in routine clinical 
practice may not reliably distinguish between CHB-AR versus 
AHB. However, this distinction may be important in prognos-
tication and planning appropriate clinical care. To date, HBV 
sequence data relating to the distinction of AHB and CHB-AR 
mostly consists of individual genes at the Sanger sequencing 
level, particularly core and pre-core genes (Table 1), and we 
have shown how this approach can help to inform a better 
understanding of a clinical case. As more deep sequence data 
are generated with better representation of diverse genotypes, 
viral sequence motifs may emerge that allow further improve-
ments to be made in determining this distinction, with the 
potential to improve insights into prognosis and underpin 
decisions about antiviral therapy. 
Methods
Plasma samples were taken at the time of index presentation 
to hospital. We extracted total nucleic acid from 0.5ml plasma, 
using the NucliSENS automated magnetic nucleic acid 
extraction system (cat. No. 280140, BioMérieux), eluting into 
25μl elution buffer, as per the manufacturer’s instructions. 
We undertook a completion-ligation reaction, incubating the 
partially double stranded (ds)DNA genome with a T4 ligase 
and T4 polymerase (cat. No. M0202S and M0203S respectively, 
both supplied from New England Biolabs) at 30°C for 
45 minutes, in order to generate fully dsDNA HBV genomes, as 
previously described31,52. Nucleic acid was then purified using 
Agencourt RNAClean XP magnetic beads (cat. No. A63987, 
Beckman Coulter). We generated sequencing libraries using 
the NEBNext Ultra II FS DNA Library Prep Kit for Illumina 
(cat. No. E7805L, New England Biolabs) according to manu-
facturer’s instructions and enriched for HBV DNA using a 
target-enrichment workflow modified from the SeqCap EZ 
(Roche) protocol, using custom-designed pangenotypic HBV 
probes spanning the full-length viral genome ordered from 
IDT (xGen Lockdown Probes). Probe sequences are not yet 
published but we welcome approaches for collaborations using 
this method; see further details in ‘data availability’ section.
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We sequenced libraries on an Illumina MiSeq platform using 
a v3 300-bp paired end kit, then demultiplexed paired-end 
Illumina reads and removed poor-quality bases and adaptor 
sequences (QUASR v7.01 and Cutadapt v1.7.1 software53,54). 
Human reads were removed by mapping to the human 
reference genome, hg19 using bowtie2 v2.2.455. We used 
BWA mem56 to map non-human reads to HBV genotype A-H 
consensus reference sequences, derived from 4500 whole 
genomes stored on HBVdb57 (sequences available from https://
github.com/hr283).
We generated a maximum likelihood phylogenetic tree using 
MEGA758 with bootstrap replicates of 1000. Based on our 
patient’s travel history to Pakistan and Malaysia, we downloaded 
all full-length HBV genome sequences from Pakistan and 
Malaysia from GenBank (April 2019)59. We included all those 
from Pakistan (n=7) and identified genotype D sequences from 
Malaysia (n=3) (see Figure 2).
To assess viral diversity, we aligned our sequence against the 
HBV sequence AX02763, (genotype A reference strain widely 
used for numbering), with the EcoR1 site as nucleotide 1. 
We calculated nucleotide variance using Shannon entropy for 
each site across the HBV genome to quantify viral diversity. 
We assessed for the presence of polymorphisms, insertions 
and deletions (indels) at consensus level and then examined 
the deep sequencing reads for evidence of minority variants. 
We set a threshold of ≥10% frequency to identify the most 
relevant polymorphisms, deletions and indels. We searched the 
literature to identify HBV sequence polymorphisms associated 
with AHB, CHB-AR and HBV-related acute-on-chronic liver 
failure (summarised in Table 1). We compared polymorphisms 
found in HBV sequences from patient 1745 with those we had 
identified from the published literature (Table 1).
Ethics
Approval for this work was provided by Oxford Research 
Ethics Committee A (reference 09/H0604/20). Written informed 
consent for publication of their clinical details was obtained 
from the patient.
Consent
We obtained written consent from this patient both for enrolment 
into the Oxford Hepatitis Cohort Study, and for his specific 
agreement to publication of this individual case report.
Data availability
Underlying data
Sequence data has been submitted to GenBank: Accession 
number MT114169.
Probe sequences
The sequences of the custom-designed HBV enrichment probe 
set used for HBV enrichment are not currently available due to 
potential collaboration with industry for commercial develop-
ment. However, we welcome applications for collaboration using 
this method, which we will consider on a case-by-case basis, 
accounting for the nature of the research question, sample set 
(available material, number of samples to be sequenced), and 
allocation of resources required for the project (funding and 
manpower). Please contact philippa.matthews@ndm.ox.ac.uk or 
azim.ansari@ndm.ox.ac.uk for further information.
Reporting guidelines
Figshare: CARE checklist for ‘Application of hepatitis B virus 
(HBV) deep sequencing to distinguish between acute and chronic 
infection’ https://doi.org/10.6084/m9.figshare.12649196.v160
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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